Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 4/20 | 0.41 |
| ▸ | IDO2 | Q6ZQW0 | 4/20 | 0.41 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | HTR7 | P34969 | 7/20 | 0.39 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24090108 | 0.90 | ACP1 (0.39) | JAK2SYK | |
| SCHEMBL29623149 | 0.90 | ACP1 (0.39) | JAK2SYK | |
| SCHEMBL24089899 | 0.89 | HTR7 (0.41) | TDO2IDO2IDO1HTR7PIK3CD | |
| SCHEMBL24089983 | 0.89 | HTR7 (0.41) | TDO2IDO2IDO1HTR7P2RX3 | |
| SCHEMBL24089965 | 0.88 | HTR7 (0.42) | TDO2IDO2IDO1HTR7P2RX3 | |
| SCHEMBL29623297 | 0.86 | IDO1 (0.55) | TDO2IDO2IDO1HTR7JAK2 | |
| SCHEMBL23065082 | 0.86 | IDO1 (0.55) | TDO2IDO2IDO1HTR7JAK2 | |
| SCHEMBL23065101 | 0.85 | MEN1 (0.48) | TDO2IDO2IDO1HTR7 | |
| SCHEMBL23065098 | 0.84 | MEN1 (0.52) | TDO2IDO2IDO1HTR7 | |
| SCHEMBL29623188 | 0.84 | MEN1 (0.52) | TDO2IDO2IDO1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352366-B2 | 2-aminoquinazolinone derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-05-12 | — | — | US | disclosed |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2021-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143020-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, CRKL | TDO2 2059/4885IDO2 398/4885IDO1 386/4885 |
| US-20210380598-A1 | 2-AMINOQUINAZOLINONE DERIVATIVE | CNKSR1, HAX1, SLC26A3 | TDO2 1774/4885IDO2 416/4885IDO1 592/4885 |
| US-11352366-B2 | 2-aminoquinazolinone derivative | CNKSR1, HAX1, SLC26A3 | TDO2 1774/4885IDO2 416/4885IDO1 592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.